Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …

Purpose Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib
Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared …

Background Tyrosine-kinase inhibitors improve overall survival in patients with chronic
myeloid leukaemia in chronic phase (CML-CP). Survival compared with the general …

Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic
myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most …

Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …

A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within
1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated …

Background Imatinib (400 mg daily) is considered the best initial therapy for patients with
newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a …